Halozyme Therapeutics, Inc. — Q1 2017 Form 10-Q
Reporting period: Three months ended March 31, 2017; balance-sheet figures are as of March 31, 2017, compared with December 31, 2016. Halozyme is a biotechnology company developing oncology therapies and licensing its ENHANZE drug-delivery technology. Its lead proprietary candidate, PEGPH20, was in Phase 3 testing for pancreatic cancer.
Financial performance
| Metric | Q1 2017 | Q1 2016 |
|---|---|---|
| Total revenue | $29.6 million | $42.5 million |
| Product sales | $11.4 million | $12.9 million |
| Royalties | $14.0 million | $11.4 million |
| Collaborative-agreement revenue | $4.2 million | $18.2 million |
| Research and development expense | $36.9 million | $40.1 million |
| Selling, general and administrative expense | $12.6 million | $10.8 million |
| Operating loss | $27.5 million | $16.2 million |
| Net loss | $32.9 million | $19.8 million |
| Basic and diluted loss per share | $0.26 | $0.16 |
| Net cash used in operating activities | $22.5 million | $13.0 million |
Product gross profit was approximately $3.9 million, or 34% of product sales, versus approximately $5.2 million, or 40%, a year earlier. The filing does not present this gross-margin measure directly; it is calculated as product sales less cost of product sales.
At March 31, cash and cash equivalents were $45.2 million and available-for-sale marketable securities were $133.8 million, totaling $179.0 million. Current assets were $222.4 million and current liabilities were $61.7 million. Total debt, net of discounts, was approximately $214.0 million: $158.9 million under the royalty-backed loan and $55.1 million under the Oxford/SVB facility. Stockholders’ deficit was $58.5 million.
Changes from the prior comparable period
- Revenue fell 30%, mainly because Q1 2016 included $15.5 million of license and milestone revenue from Lilly, AbbVie and Pfizer; no such revenue was recognized in Q1 2017.
- Royalties increased 23%, reflecting higher reported sales of Roche’s Herceptin SC and MabThera SC and Baxalta’s HYQVIA.
- Product sales declined 12%, primarily from lower Roche bulk rHuPH20 sales and lower Hylenex sales. Management said Roche was expected to draw down existing inventory ahead of a manufacturing-facility transition, likely reducing Roche bulk sales in 2017 and 2018.
- Net loss widened by $13.1 million. Lower R&D expense was more than offset by lower revenue, higher SG&A and higher interest expense. Interest expense rose to $5.4 million, largely reflecting a full quarter of interest on the royalty-backed loan.
- Operating cash use increased by $9.4 million. Cash, cash equivalents and restricted cash declined $21.6 million during the quarter.
Outlook, risks and notable items
- Management said the $179.0 million of cash, cash equivalents and marketable securities should fund operations for at least the next 12 months. It also cautioned that resources may not fund operations until profitability, if ever, and additional financing may be needed. A February 2017 automatic shelf registration permits future securities offerings.
- Management expected royalties generally to grow with collaborator product sales, while noting period-to-period variability. It expected Hylenex sales to be flat or grow modestly, with possible declines from competition; Roche bulk rHuPH20 sales were expected to be lower during the facility transition. PEGPH20 spending was expected to increase, while Roche-related manufacturing and service activity was expected to decrease after facility validation.
- The Phase 3 PEGPH20 pancreatic-cancer study continued; the safety monitoring committee advised that it proceed as planned. The FDA advisory committee voted 11–0 in favor of the benefit-risk profile of Roche’s subcutaneous rituximab for proposed CLL and lymphoma indications; the FDA action date was June 26, 2017.
- SWOG stopped enrollment in a PEGPH20 plus modified FOLFIRINOX pancreatic-cancer study after a planned futility review found it unlikely to show a statistically significant overall-survival improvement in the all-comer population; SWOG also reported a higher death rate in the PEGPH20 arm. Halozyme said its PEGPH20 studies with other agents continued unchanged.
- In the earlier Study 109-202, management reported statistically significant progression-free-survival findings in the combined HA-High analysis. Stage 2 results were based on a small HA-High group, and the database was still open; updated analysis was pending completion and lock.
- The royalty-backed loan bears interest at 9.9% as of quarter-end; repayment depends on royalty receipts. Management estimated repayment in Q1 2020, but said lower-than-expected royalties could extend the term. The Oxford/SVB loan is secured by substantially all company assets, subject to exclusions, and includes restrictive covenants. The company reported compliance with both loan agreements.
- Halozyme planned to adopt the new revenue-recognition standard on January 1, 2018, likely using the modified retrospective method. It anticipated a material financial-statement impact, including changes to recognition timing for certain collaboration payments and sales-based royalties; the amount was not yet reasonably estimable.
- The company reported no legal proceedings expected by management to have a material adverse effect. Disclosure controls were considered effective, with no significant change in internal control reported for the quarter.
Most important facts for investors to verify
- Progress, enrollment, safety and efficacy results for the Phase 3 PEGPH20 trial, and the implications of the stopped SWOG study.
- Whether collaborator sales sustain royalty growth and how the Roche manufacturing transition affects bulk product revenue.
- Cash burn, financing needs and any use of the shelf registration; confirm liquidity against ongoing clinical-trial spending.
- Royalty-backed loan repayment assumptions, interest burden, and compliance with secured-loan covenants.
- The quantified effects of adopting the new revenue-recognition standard once Halozyme completes its assessment.